TBPH vs. ANNX, PLRX, AKRO, KNSA, SDGR, ARDX, TARO, EWTX, LGND, and MORF
Should you be buying Theravance Biopharma stock or one of its competitors? The main competitors of Theravance Biopharma include Annexon (ANNX), Pliant Therapeutics (PLRX), Akero Therapeutics (AKRO), Kiniksa Pharmaceuticals (KNSA), Schrödinger (SDGR), Ardelyx (ARDX), Taro Pharmaceutical Industries (TARO), Edgewise Therapeutics (EWTX), Ligand Pharmaceuticals (LGND), and Morphic (MORF). These companies are all part of the "pharmaceutical preparations" industry.
Annexon (NASDAQ:ANNX) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.
Annexon has a net margin of 0.00% compared to Annexon's net margin of -72.79%. Annexon's return on equity of -18.97% beat Theravance Biopharma's return on equity.
Theravance Biopharma has higher revenue and earnings than Annexon. Theravance Biopharma is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.
Annexon has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.36, suggesting that its share price is 64% less volatile than the S&P 500.
99.1% of Theravance Biopharma shares are held by institutional investors. 12.7% of Annexon shares are held by company insiders. Comparatively, 6.9% of Theravance Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Theravance Biopharma received 293 more outperform votes than Annexon when rated by MarketBeat users. However, 73.33% of users gave Annexon an outperform vote while only 63.47% of users gave Theravance Biopharma an outperform vote.
Annexon currently has a consensus target price of $15.33, indicating a potential upside of 217.46%. Theravance Biopharma has a consensus target price of $20.50, indicating a potential upside of 137.82%. Given Theravance Biopharma's higher possible upside, equities analysts plainly believe Annexon is more favorable than Theravance Biopharma.
In the previous week, Theravance Biopharma had 5 more articles in the media than Annexon. MarketBeat recorded 8 mentions for Theravance Biopharma and 3 mentions for Annexon. Theravance Biopharma's average media sentiment score of 0.71 beat Annexon's score of 0.21 indicating that Annexon is being referred to more favorably in the media.
Summary
Annexon and Theravance Biopharma tied by winning 8 of the 16 factors compared between the two stocks.
Get Theravance Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Theravance Biopharma Competitors List
Related Companies and Tools
